Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

NCT05878184 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: SC291

Sponsor

Sana Biotechnology